Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|RTOG-0436||RTOG||A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel; Cisplatin; and Radiation for Patients with Esophageal Cancer who are Treated without Surgery||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACOSOG-Z1031||ACSOG||A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily); Letrozole (2.5 mg); or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-30102||CALGB||Phase III Comparison of Catheter Based Therapy of Pleural Effusions in Cancer Patients (Optimal Pleural Effusion Control; OPEC||Adult CIRB - Late Phase Emphasis||Completed|
|S0303||SWOG||A Phase III Trial of Modified FOLFOX6 Versus CAPOX; with Bevacizumab (NSC-704865) or Placebo; as First-Line Therapy in Patients with Previously Untreated Advanced Colorectal Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S1929||SWOG||Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NCIC-MA.27B||NCIC CTG||The Influence of Five Years of Adjuvant Anastrozole or Exemestane on bone Mineral Density in Postmenopausal Women with Primary Breast Cancer - A Companion Study to NCIC CTG MA.27||Adult CIRB - Late Phase Emphasis||Completed|
|NRG-GY004||NRG||Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian; Fallopian Tube; or Primary Peritoneal Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1418||SWOG||A Randomized; Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/=1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0263||GOG||Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk; Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy <br><br>||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-BN003||NRG||Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma||Adult CIRB - Late Phase Emphasis||Available to Open|